171 related articles for article (PubMed ID: 33104197)
1. Tofacitinib and Subacute Pneumonitis: Don't Hold Your Breath.
Verstockt B; Pouillon L; Bossuyt P
J Crohns Colitis; 2021 Apr; 15(4):692-693. PubMed ID: 33104197
[No Abstract] [Full Text] [Related]
2. Multiple esophageal ulcers due to tofacitinib 10 mg twice daily for ulcerative colitis.
Tominaga K; Kanazawa M; Takenaka K; Tanaka T; Sugaya T; Fukushi K; Takagi Y; Nagashima K; Abe K; Izawa N; Tsuchida K; Iijima M; Goda K; Yamagishi H; Irisawa A
Clin J Gastroenterol; 2020 Jun; 13(3):340-343. PubMed ID: 31705375
[TBL] [Abstract][Full Text] [Related]
3. Exposure to Tofacitinib Not Related to Recurrence of Anal Premalignant Lesion: A Case Report.
Queiroz NSF; Graciolli CB; Sobrado CW
Inflamm Bowel Dis; 2020 Nov; 26(12):e155-e156. PubMed ID: 32676668
[No Abstract] [Full Text] [Related]
4. Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis.
Sandborn WJ; Su C; Sands BE; D'Haens GR; Vermeire S; Schreiber S; Danese S; Feagan BG; Reinisch W; Niezychowski W; Friedman G; Lawendy N; Yu D; Woodworth D; Mukherjee A; Zhang H; Healey P; Panés J;
N Engl J Med; 2017 May; 376(18):1723-1736. PubMed ID: 28467869
[TBL] [Abstract][Full Text] [Related]
5. Tofacitinib Treatment Is Associated With Modest and Reversible Increases in Serum Lipids in Patients With Ulcerative Colitis.
Sands BE; Taub PR; Armuzzi A; Friedman GS; Moscariello M; Lawendy N; Pedersen RD; Chan G; Nduaka CI; Quirk D; Salese L; Su C; Feagan BG
Clin Gastroenterol Hepatol; 2020 Jan; 18(1):123-132.e3. PubMed ID: 31077827
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of tofacitinib treatment in ulcerative colitis.
Panés J; Gisbert JP
Gastroenterol Hepatol; 2019; 42(6):403-412. PubMed ID: 31101342
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of biologic agents and tofacitinib in moderate-to-severe ulcerative colitis: A systematic overview of meta-analyses.
Pantavou K; Yiallourou AI; Piovani D; Evripidou D; Danese S; Peyrin-Biroulet L; Bonovas S; Nikolopoulos GK
United European Gastroenterol J; 2019 Dec; 7(10):1285-1303. PubMed ID: 31839954
[TBL] [Abstract][Full Text] [Related]
8. Tofacitinib for the treatment of ulcerative colitis.
Izzo R; Bevivino G; Monteleone G
Expert Opin Investig Drugs; 2016 Aug; 25(8):991-7. PubMed ID: 27177233
[TBL] [Abstract][Full Text] [Related]
9. Colombian experience with the use of tofacitinib in severe acute ulcerative colitis: A case series study.
Parra-Izquierdo V; Frías-Ordoñez JS; Juliao-Baños F; Cuadros C; Romero Sanchez C; Flórez-Sarmiento C
Gastroenterol Hepatol; 2024; 47(6):582-590. PubMed ID: 37806342
[TBL] [Abstract][Full Text] [Related]
10. Experience with tofacitinib in patients with refractary ulcerative colitis.
López González J; Hernández Martínez Á; Lázaro Sáez M; Vega Sáenz JL
Gastroenterol Hepatol; 2021 Apr; 44(4):300-301. PubMed ID: 33051048
[No Abstract] [Full Text] [Related]
11. Tofacitinib in Acute Severe Ulcerative Colitis-A Real-World Tertiary Center Experience.
Honap S; Pavlidis P; Ray S; Sharma E; Anderson S; Sanderson JD; Mawdsley J; Samaan MA; Irving PM
Inflamm Bowel Dis; 2020 Oct; 26(11):e147-e149. PubMed ID: 32566937
[No Abstract] [Full Text] [Related]
12. [Tofacitinib for the treatment of ulcerative colitis. Report of two cases].
Quera R; Flores L; Núñez P; Ibáñez P
Rev Med Chil; 2020 Jul; 148(7):1039-1043. PubMed ID: 33399691
[No Abstract] [Full Text] [Related]
13. Use of Tofacitinib for Ulcerative Colitis in a Liver Transplant Patient.
Meunier L; Clerc C; Meszaros M
J Crohns Colitis; 2021 Apr; 15(4):695. PubMed ID: 32072164
[No Abstract] [Full Text] [Related]
14. Tofacitinib 2% ointment, a topical Janus kinase inhibitor, for the treatment of alopecia areata: A pilot study of 10 patients.
Liu LY; Craiglow BG; King BA
J Am Acad Dermatol; 2018 Feb; 78(2):403-404.e1. PubMed ID: 29108908
[No Abstract] [Full Text] [Related]
15. [Tofacitinib].
Döker S; Dewenter M; El-Armouche A
Dtsch Med Wochenschr; 2014 May; 139(19):1003-8. PubMed ID: 24782154
[TBL] [Abstract][Full Text] [Related]
16. Herpes Zoster Infection in Patients With Ulcerative Colitis Receiving Tofacitinib.
Winthrop KL; Melmed GY; Vermeire S; Long MD; Chan G; Pedersen RD; Lawendy N; Thorpe AJ; Nduaka CI; Su C
Inflamm Bowel Dis; 2018 Sep; 24(10):2258-2265. PubMed ID: 29850873
[TBL] [Abstract][Full Text] [Related]
17. Tofacitinib in ulcerative colitis.
Archer TP; Moran GW; Ghosh S
Immunotherapy; 2016 May; 8(5):495-502. PubMed ID: 27140405
[TBL] [Abstract][Full Text] [Related]
18. Herpes zoster as a cause of atypical chronic ulcerations associated with tofacitinib.
Noell C; Arbeit R; Kanhoush R
Dermatol Online J; 2018 Jan; 24(1):. PubMed ID: 29469766
[TBL] [Abstract][Full Text] [Related]
19. A case of Takayasu arteritis complicated by refractory ulcerative colitis successfully treated with tofacitinib.
Sato S; Matsumoto H; Temmoku J; Fujita Y; Matsuoka N; Furuya M; Gunji N; Fujiwara T; Asano T; Onizawa M; Kobayashi H; Watanabe H; Ohira H; Migita K
Rheumatology (Oxford); 2020 Jul; 59(7):1773-1775. PubMed ID: 31776552
[No Abstract] [Full Text] [Related]
20. Real-world evidence of tofacitinib effectiveness and safety in patients with refractory ulcerative colitis.
Lair-Mehiri L; Stefanescu C; Vaysse T; Laharie D; Roblin X; Rosa I; Treton X; Abitbol V; Amiot A; Bouguen G; Dib N; Fumery M; Pariente B; Carbonnel F; Peyrin-Biroulet L; Simon M; Viennot S; Bouhnik Y
Dig Liver Dis; 2020 Mar; 52(3):268-273. PubMed ID: 31732444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
